EGFR and non-small cell lung carcinoma: For instance, one of the largest cohorts of secondary resistance in aNSCLC (n = 51 patients under anti-PD-1/PD-L1 monotherapy) originates from Korea and comprises a high proportion of EGFR-mutated NSCLC (≥17.4%) [23].